Janney Montgomery Scott LLC increased its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 4.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 305,395 shares of the pharmaceutical company's stock after purchasing an additional 13,239 shares during the quarter. Janney Montgomery Scott LLC's holdings in GSK were worth $11,831,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Dorsey & Whitney Trust CO LLC increased its holdings in GSK by 2.5% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after buying an additional 278 shares in the last quarter. Northwest Bank & Trust Co boosted its stake in shares of GSK by 1.3% during the 4th quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after acquiring an additional 289 shares in the last quarter. GC Wealth Management RIA LLC grew its holdings in shares of GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after acquiring an additional 353 shares during the period. Rhumbline Advisers increased its stake in GSK by 2.1% in the 1st quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company's stock valued at $713,000 after purchasing an additional 386 shares in the last quarter. Finally, Jacobi Capital Management LLC increased its stake in GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after purchasing an additional 389 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.
GSK Price Performance
GSK stock traded down $0.65 during midday trading on Friday, reaching $37.99. 8,245,796 shares of the company were exchanged, compared to its average volume of 4,929,766. The firm's 50-day simple moving average is $38.58 and its 200-day simple moving average is $36.81. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.67. The company has a market capitalization of $77.79 billion, a price-to-earnings ratio of 19.58, a P/E/G ratio of 1.35 and a beta of 0.52. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.
GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.43 EPS. On average, analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.
GSK Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.44%. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is 87.11%.
Analyst Upgrades and Downgrades
Several analysts have weighed in on the company. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Finally, BNP Paribas assumed coverage on shares of GSK in a report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, GSK has a consensus rating of "Hold" and an average price target of $37.38.
Read Our Latest Research Report on GSK
GSK Company Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
